About: Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures
Creator	Ho, T-Y Hsiang, C-Y
Source	Medline; PMC
abstract	BACKGROUND AND PURPOSE: Most antiviral therapies directed against herpes simplex virus (HSV) infections are limited to a small group of nucleoside analogues that target the viral polymerase. Extensive clinical use of these drugs has led to the emergence of resistant viral strains, mainly in immunocompromised patients. This highlights the need for the development of new anti-herpesviral drugs with novel targets. Herein the effects of a plant anthraquinone, emodin, on the HSV-1 alkaline nuclease activity and virus yields were investigated. EXPERIMENTAL APPROACH: HSV-1 alkaline nuclease activity was examined by nuclease activity assay. Inhibition of virus yields was measured by plaque reduction assay and immunohistochemical staining. Interaction between emodin and alkaline nuclease was analysed by docking technology. KEY RESULTS: Emodin specifically inhibited the nuclease activity of HSV-1 UL12 alkaline nuclease in a biochemical assay. Plaque reduction assay revealed that emodin reduced the plaque formation with an EC(50) of 21.5±4.4 μM. Immunohistochemical staining using the anti-nucleocapsid protein antibody demonstrated that emodin induced the accumulation of viral nucleocapsids in the nucleus in a dose-dependent manner. Docking analysis further suggested that the inhibitory effect of emodin on the UL12 activity may result from the interaction between emodin and critical catalytic amino acid residues of UL12. CONCLUSIONS AND IMPLICATIONS: Our findings suggest that emodin is a potent anti-HSV agent that inhibits the yields of HSV-1 via the suppression of a novel target, UL12.
has issue date	2009-01-29(xsd:dateTime)
bibo:doi	10.1038/bjp.2008.242
bibo:pmid	18552872
has license	green-oa
sha1sum (hex)	1ab3be28a3e67aca45aede2cecae9339848254a7
schema:url	https://doi.org/10.1038/bjp.2008.242
resource representing a document's title	Emodin is a novel alkaline nuclease inhibitor that suppresses herpes simplex virus type 1 yields in cell cultures
has PubMed Central identifier	PMC2538697
has PubMed identifier	18552872
schema:publication	British Journal of Pharmacology
resource representing a document's body	covid:1ab3be28a3e67aca45aede2cecae9339848254a7#body_text
is schema:about of	named entity 'PLAQUE' named entity 'ANALYSIS' named entity 'ANTHRAQUINONE' named entity 'NUCLEUS' named entity 'CATALYTIC' named entity 'DIRECTED' named entity 'NUCLEOSIDE ANALOGUES' named entity 'ALKALINE' named entity '4.4' named entity 'SUPPRESSION' named entity 'USE OF' named entity 'EXAMINED' named entity 'NUCLEASE ACTIVITY' named entity 'IMMUNOHISTOCHEMICAL STAINING' named entity 'NUCLEASE' named entity 'DRUGS' named entity 'directed' named entity 'interaction' named entity 'dose-dependent' named entity 'induced' named entity 'therapies' named entity 'assay' named entity 'immunohistochemical staining' named entity 'revealed' named entity 'potent' named entity 'immunocompromised' named entity 'cell cultures' named entity 'simplex' named entity 'NOVEL' covid:arg/1ab3be28a3e67aca45aede2cecae9339848254a7 named entity '4 MM' named entity 'PLANT' named entity 'FINDINGS' named entity 'VIRAL' named entity 'HSV-1' named entity 'PROTEIN ANTIBODY' named entity 'ALKALINE' named entity 'SUPPRESSES' named entity 'EMODIN' named entity 'HERPES SIMPLEX VIRUS TYPE 1' named entity 'ASSAY' named entity 'NEW' named entity 'DEMONSTRATED' named entity 'TARGETS' named entity 'EMERGENCE' named entity 'STRAINS' named entity 'SUGGEST' named entity 'USING' named entity 'ANTI-HSV AGENT' named entity 'CONCLUSIONS' named entity 'IMMUNOCOMPROMISED PATIENTS' named entity 'TARGET' named entity 'MEASURED' named entity 'LED' named entity 'THESE' named entity 'CELL CULTURES' named entity 'NUCLEASE INHIBITOR' named entity 'IS A' named entity 'INDUCED' named entity 'ACTIVITY' named entity 'OUR' named entity 'HERPES SIMPLEX VIRUS' named entity 'THERAPIES' named entity 'NOVEL' named entity 'DOCKING' named entity 'EXTENSIVE' named entity 'BACKGROUND' named entity 'LIMITED' named entity 'VIRAL POLYMERASE' named entity 'VIRUS' named entity 'PURPOSE' named entity 'NEED FOR' named entity 'AMINO ACID' named entity 'TECHNOLOGY' named entity 'CRITICAL' named entity 'ANTIHERPESVIRAL DRUGS' named entity 'SMALL GROUP' named entity 'IS A' named entity 'BIOCHEMICAL ASSAY' named entity 'NUCLEOCAPSID PROTEIN'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software